Canadian listed Medicago Inc (TSX-V: MDG) announced that it had entered into a partnership agreement with Evry, France based Genepole ® to build a flu vaccine manufacturing facility.
The facility will use Midicago’s Proficia ™ plant-based manufacturing technology and VLP vaccine technology. The facility will be built on Genepole’s site in Evry, France, and will produce pandemic and seasonal flu vaccines and other ‘biodefense’ related products.
Construction of the facility is conditional upon Medicago's successful completion of a Phase I clinical trial with its H5N1 pandemic influenza vaccine, and a “reasonable level of commitment” by the French authorities to support this novel technology.
"We are proud to be working with Genopole to contribute towards the strengthening of France's health infrastructure," said Andy Sheldon, President and CEO of Medicago. "This agreement is in line with our strategy to export our rapid and cost-effective solution for the manufacturing of influenza vaccines to enable countries worldwide to produce their own vaccines, within their own borders."
"We are delighted to be working with Medicago and their innovative non-transgenic, plant-based manufacturing technology which has great promise for the development of vaccines," said Pierre Tambourin, Director of Genopole. "This new facility will support our biopark's leadership in innovation and bioproduction by offering unique manufacturing capabilities to France and Europe."
www.proactiveinvestors.com
Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
No comments:
Post a Comment